EMPOWER-Lung1 and 3 Squamous Subgroup Analysis: Expert Insights
January 26th 2024Edgardo Santos, MD, FACP, FCCP, offers expert insights into the squamous subgroup analysis of EMPOWER-Lung1 and 3, shedding light on the implications of these data for the treatment of individuals with squamous non-small cell lung cancer (NSCLC).
Read More
EMPOWER-Lung3: Cemiplimab Plus Chemotherapy in Advanced NSCLC
January 19th 2024Edgardo Santos, MD, FACP, FCCP, analyzes the influence on clinical practice arising from the application of cemiplimab with chemotherapy in advanced non-small cell lung cancer (NSCLC) observed in the EMPOWER-Lung3 trial.
Read More
Expert Perspectives on the Latest TROPION-Lung01 Data
January 19th 2024Edgardo Santos, MD, FACP, FCCP, provides expert insights into the latest data from the TROPION-Lung01 trial, emphasizing the potential implications of this information for treating patients with non-actionable biomarkers in NSCLC.
Read More
Expert Analysis on Recent Developments in DESTINY-Lung01 and DESTINY-Lung02 Trials
January 12th 2024Edgardo Santos, MD, FACP, FCCP, analyzes the recent developments in the DESTINY-Lung01 and DESTINY-Lung02 trials, specifically focusing on HER2+ NSCLC patients with brain metastases and exploring the potential impact on clinical practice.
Read More
Beamion Lung 1: Zongertinib (BI 1810631) in Advanced HER2+ NSCLC
January 12th 2024Edgardo Santos, MD, FACP, FCCP, provides insights into the innovative Beamion Lung 1 trial, focused on assessing the safety and tolerability of zongertinib (BI 1810631) in patients with advanced, previously treated HER2+ non-small cell lung cancer (NSCLC).
Read More
Dr Santos on Steps Taken to Address the Chemotherapy Shortage in the United States
August 8th 2023Edgardo Santos MD, FACP, FCCP, discusses how cancer centers across the United States are minimizing the negative effects of the ongoing carboplatin and cisplatin shortage, and details potential next steps that should be taken to prevent drug shortages like this from occurring in the future.
Read More
Dr Santos on Frontline Therapies in ALK+ NSCLC
July 7th 2023Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; treasurer, Florida Society of Clinical Oncology, discusses first-line treatment options for patients with ALK-positive non–small cell lung cancer.
Read More
Dr Santos on the Evolution of Osimertinib in EGFR Mutated NSCLC
May 31st 2023Edgardo S. Santos, MD, FACP, discusses the evolution of osimertinib in the treatment of patients with EGFR-mutated non–small cell lung cancer and the updated data that reaffirmed its role in the adjuvant setting for this patient population.
Read More
Unmet Needs and Future Directions in the Management of CIM
July 22nd 2022Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.
Read More
Trilaciclib Efficacy in the Prevention of CIM in ES-SCLC
July 15th 2022Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.
Read More
Dr. Santos on the FDA Approval of Ramucirumab/Erlotinib in EGFR-Mutant NSCLC
May 30th 2020Edgardo S. Santos, MD, FACP, FCCP, discusses the FDA approval of the combination of ramucirumab and erlotinib for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.
Read More